Moleculin Biotech increases ATM stock offering size to $19.7 million
The company filed a prospectus supplement dated August 21, 2026, expanding the amount it can sell through its at-the-market agreement with Roth Capital Partners.
SEC filing
Latest
6 stories
Tuesday, September 29
Friday, August 21
Friday, August 14
Moleculin reports positive interim MIRACLE data, keeps trial timeline on track
The company said complete remission rates were at least three times higher than control in the first 45 patients, with 90-patient enrollment still targeted for September 2026.
SEC filing
Monday, August 3
Moleculin prices $9.3M offering of stock and warrants at $0.75/share
Moleculin Biotech priced a public offering of common stock, pre-funded warrants, and common warrants, with share delivery expected around August 3, 2026.
SEC filing (2)
Moleculin Biotech closes $9.3 million public offering with Roth Capital as placement agent
The offering priced shares and warrants at $0.75 apiece, with proceeds earmarked for Annamycin development and working capital.
SEC filing
Friday, July 31
Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trial
Interim blinded data from 62 evaluable subjects show remission rates holding steady even as more venetoclax-failure patients enter the pivotal trial.
SEC filing